pharmaceuticals

pharmaceuticals Articles

Shares of IntelliPharmaCeutics soared after the company reported a new licensing deal with Mallinckrodt.
Accelerated Pharma intends to price less than 2 million shares in the range of $8 to $10 for an initial public offering valued up to more than $21 million.
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
Biostar Pharmaceuticals Inc. (NASDAQ: BSPM) is watching its shares nearly double on Tuesday after the company announced that it is releasing a new product line to treat respiratory irritation and...
Nymox Pharmaceutical shares jumped following the announcement of positive results from its late-stage prostate cancer trial.
KemPharm shares saw a solid gain on Tuesday following a key FDA approval on it treatment for attention deficit hyperactivity disorder.
Shares of EpiPen maker Mylan NV (NASDAQ: MYL) rose nearly 12.5% early Monday following the company’s announcement after markets closed Friday that it had reached an agreement with the U.S....
Several analysts have weighed in with higher price targets on top of their ratings for Tesaro. Its shares hit a new 52-week high on Monday.
On Monday morning, Merck, Mylan and Bristol-Myers Squibb made substantial runs, either up or down.
Shares of Idera Pharmaceuticals sank on Thursday after the company announced that it intends to have a secondary offering.
Alnylam Pharmaceuticals saw its shares crash on Thursday after the company announced that it will be discontinuing one of its late-stage trials.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has been on a meteoric rise over the past month. In this time the stock has gained over 150%, on what has been relatively little news for such a massive...
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
Scynexis shares made a handy gain early on Thursday after the company announced the results from a couple of its mid-stage trials.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.